About Tempest Therapeutics, Inc.
https://www.tempesttx.comTempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer.
CEO
Stephen R. Brady
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-04-09 | Reverse | 1:13 |
| 2021-06-28 | Reverse | 1:15 |
ETFs Holding This Stock
Summary
Showing Top 2 of 13
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:550.24K
Value:$1.5M
VERSANT VENTURE MANAGEMENT, LLC
Shares:269.77K
Value:$733.78K
CUTLER GROUP LLC / CA
Shares:210
Value:$571.2
Summary
Showing Top 3 of 3
About Tempest Therapeutics, Inc.
https://www.tempesttx.comTempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $3.53M ▼ | $-3.51M ▲ | 0% | $-0.79 ▲ | $-3.44M ▲ |
| Q2-2025 | $0 | $7.9M ▼ | $-7.87M ▲ | 0% | $-2.07 ▲ | $-7.76M ▲ |
| Q1-2025 | $0 | $10.94M ▼ | $-10.86M ▲ | 0% | $-3.16 ▼ | $-10.63M ▲ |
| Q4-2024 | $0 | $13.92M ▲ | $-13.81M ▼ | 0% | $-0.5 ▼ | $-13.52M ▼ |
| Q3-2024 | $0 | $10.55M | $-10.56M | 0% | $-0.41 | $-10.13M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $7.51M ▼ | $17.13M ▼ | $10.78M ▼ | $6.35M ▼ |
| Q2-2025 | $14.28M ▼ | $24.48M ▼ | $14.7M ▼ | $9.78M ▼ |
| Q1-2025 | $21.51M ▼ | $32.16M ▼ | $21.03M ▼ | $11.13M ▼ |
| Q4-2024 | $30.27M ▲ | $41.49M ▲ | $22.36M ▼ | $19.13M ▲ |
| Q3-2024 | $22.12M | $33.84M | $22.38M | $11.46M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-3.51M ▲ | $-6.78M ▲ | $0 | $13K ▼ | $-6.77M ▲ | $-6.78M ▲ |
| Q2-2025 | $-7.87M ▲ | $-8.43M ▼ | $0 | $1.2M ▲ | $-7.23M ▲ | $-8.43M ▼ |
| Q1-2025 | $-10.86M ▲ | $-8.04M ▲ | $0 ▲ | $-721K ▼ | $-8.76M ▼ | $-8.04M ▲ |
| Q4-2024 | $-13.81M ▼ | $-10.15M ▲ | $-3K ▲ | $17.95M ▲ | $7.8M ▲ | $-10.15M ▲ |
| Q3-2024 | $-10.56M | $-10.18M | $-15K | $1.54M | $-8.66M | $-10.2M |
CEO
Stephen R. Brady
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-04-09 | Reverse | 1:13 |
| 2021-06-28 | Reverse | 1:15 |
ETFs Holding This Stock
Summary
Showing Top 2 of 13
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:550.24K
Value:$1.5M
VERSANT VENTURE MANAGEMENT, LLC
Shares:269.77K
Value:$733.78K
CUTLER GROUP LLC / CA
Shares:210
Value:$571.2
Summary
Showing Top 3 of 3